Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 6/20 | 0.58 |
| ▸ | BMP1 | P13497 | 3/20 | 0.56 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.56 |
| ▸ | PTGES | O14684 | 1/20 | 0.56 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 8/20 | 0.53 |
| ▸ | MMP9 | P14780 | 8/20 | 0.53 |
| ▸ | MMP8 | P22894 | 7/20 | 0.53 |
| ▸ | MMP13 | P45452 | 6/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6389646 | 1.00 | TAS2R14 (0.58) | TAS2R14BMP1CXCR3PTGESTAS2R8 | |
| SCHEMBL11956143 | 0.85 | BMP1 (0.54) | TAS2R14BMP1CXCR3PTGESTAS2R8 | |
| SCHEMBL5463131 | 0.85 | BMP1 (0.54) | TAS2R14BMP1CXCR3PTGESTAS2R8 | |
| SCHEMBL6388613 | 0.83 | MMP2 (0.71) | BMP1MMP2MMP9MMP8MMP13 | |
| SCHEMBL6388611 | 0.83 | MMP2 (0.71) | BMP1MMP2MMP9MMP8MMP13 | |
| SCHEMBL8016350 | 0.83 | BMP1 (0.51) | TAS2R14BMP1CXCR3PTGESTAS2R8 | |
| SCHEMBL7695749 | 0.83 | MMP2 (0.58) | TAS2R14CXCR3PTGESTAS2R8MMP2 | |
| SCHEMBL7695753 | 0.83 | MMP2 (0.58) | TAS2R14CXCR3PTGESTAS2R8MMP2 | |
| SCHEMBL7091056 | 0.81 | MMP2 (0.76) | TAS2R14BMP1CXCR3PTGESTAS2R8 | |
| SCHEMBL7091051 | 0.81 | MMP2 (0.76) | TAS2R14BMP1CXCR3PTGESTAS2R8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6844366-B2 | Sulfonamide hydroxamates | SYNTEX (U.S.A.) LLC (US) | 2005-01-18 | — | — | US | disclosed |
| US-6787559-B2 | HYDROXYCARBONYL OR ALKYLOXYCARBONYL OR AMINOHYDROXYCARBONYL SUBSTITUTED SULFONAMIDE COMPOUNDS USEFUL AS PROCOLLAGEN C-PROTENASE INHIBITOR | SYNTEX (U.S.A.) LLC. | 2004-09-07 | — | — | US | disclosed |
| EP-1149072-B1 | SULFONAMIDE HYDROXAMATES | HOFFMANN LA ROCHE (CH) | 2004-06-30 | — | — | EP | disclosed |
| US-20030216405-A1 | Hydroxycarbonyl or alkyloxycarbonyl or aminohydroxycarbonyl substituted sulfonamide compounds useful as procollagen C-protenase inhibitor | BILLLEDEAU ROLAND JOSEPH (US) | 2003-11-20 | — | — | US | disclosed |
| US-20030199520-A1 | Sulfonamide hydroxamates | BILLLEDEAU ROLAND JOSEPH (US) | 2003-10-23 | — | — | US | disclosed |
| US-6492394-B1 | PROCOLLAGEN C-PROTEINASE INHIBITORS; TREATING FIBROTIC DISEASES | SYNTEX (U.S.A.) LLC | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216405-A1 | Hydroxycarbonyl or alkyloxycarbonyl or aminohydroxycarbonyl substituted sulfonamide compounds useful as procollagen C-protenase inhibitor | CTSE, PREP, HPN | TAS2R14 4353/4885BMP1 1767/4885CXCR3 3962/4885 |
| US-20030199520-A1 | Sulfonamide hydroxamates | MMP3, TIMP3, MMP13 | TAS2R14 2214/4885BMP1 1730/4885CXCR3 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.